EGFR and non-small cell lung carcinoma: The median PFS for first-generation EGFR-TKIs combined with bevacizumab ranged from 15.4 to 17.9 months [13–16], with a median OS of 33.3 to 50.7 months in patients with advanced EGFR-mutated NSCLC [13,14,16,17].